Please use this identifier to cite or link to this item:

TitleCandida glabrata biofilms: How far have we come?
Author(s)Rodrigues, Célia Fortuna
Rodrigues, Maria Elisa Costa
Silva, Sónia Carina
Henriques, Mariana
KeywordsCandida species
Candida glabrata
Issue dateMar-2017
JournalJournal of Fungi
CitationRodrigues, Célia F.; Rodrigues, M. Elisa; Silva, Sónia Carina; Henriques, Mariana, Candida glabrata biofilms: How far have we come?. Journal of Fungi, 3(1), 11, 2017. doi: 10.3390/jof3010011
Abstract(s)Infections caused by Candida species have been increasing in the last decades and can result in local or systemic infections, with high morbidity and mortality. After Candida albicans, Candida glabrata is one of the most prevalent pathogenic fungi in humans. In addition to the high antifungal drugs resistance and inability to form hyphae or secret hydrolases, C. glabrata retain many virulence factors that contribute to its extreme aggressiveness and result in a low therapeutic response and serious recurrent candidiasis, particularly biofilm formation ability. For their extraordinary organization, especially regarding the complex structure of the matrix, biofilms are very resistant to antifungal treatments. Thus, new approaches to the treatment of C. glabratas biofilms are emerging. In this article, the knowledge available on C. glabratas resistance will be highlighted, with a special focus on biofilms, as well as new therapeutic alternatives to control them.
Publisher version
AccessOpen access
Appears in Collections:CEB - Publicações em Revistas/Séries Internacionais / Publications in International Journals/Series

Files in This Item:
File Description SizeFormat 
document_46710_1.pdf3,22 MBAdobe PDFView/Open

Partilhe no FacebookPartilhe no TwitterPartilhe no DeliciousPartilhe no LinkedInPartilhe no DiggAdicionar ao Google BookmarksPartilhe no MySpacePartilhe no Orkut
Exporte no formato BibTex mendeley Exporte no formato Endnote Adicione ao seu ORCID